A prognostic scoring system for conversion surgery after trastuzumab-based chemotherapy for human epidermal growth factor receptor 2-positive advanced gastric cancer.
Takaaki ArigamiDaisuke MatsushitaKeishi OkuboMasataka ShimonosonoKen SasakiYusuke TsurudaYoshiaki KitaKan TanabeShinichiro MoriShigehiro YanagitaYoshikazu UenosonoAkihiro NakajoHiroshi KuraharaTakao OhtsukaPublished in: Surgery today (2022)
Our scoring system has the clinical potential to predict prognosis associated with conversion surgery after trastuzumab-containing chemotherapy for patients with HER2-positive AGC.
Keyphrases
- epidermal growth factor receptor
- minimally invasive
- tyrosine kinase
- advanced non small cell lung cancer
- coronary artery bypass
- locally advanced
- endothelial cells
- surgical site infection
- neoadjuvant chemotherapy
- squamous cell carcinoma
- radiation therapy
- human health
- risk assessment
- coronary artery disease
- atrial fibrillation
- metastatic breast cancer
- pluripotent stem cells